X-Rx announces FDA acceptance of IND for X-165, a potential treatment for Idiopathic Pulmonary Fibrosis

US-based biotech company X-Rx has received a major boost in its quest to develop new treatments for Idiopathic Pulmonary Fibrosis (IPF) with the US Food ... Read More